Industry News

• ImmunoGen announces successful completion of interim analysis for FORWARD I phase 3 trial   ImmunoGen announced the FORWARD I Phase 3 registration trial evaluating mirvetuximab soravtansine as a single-agent therapy for treatment of platinum-resistant ovarian cancer will continue as planned without modification.
  April 26, 2018  
• Marrone Bio Innovations announces exercise of over-allotment option in public offering  Marrone Bio Innovations announced the underwriter of its previously announced public offering of registered shares of the Company’s common stock has fully exercised its option to purchase an additional 1,091,250 shares of common stock from the Company at the public offering price of $1.65 per share.
  April 26, 2018  
• NIH study finds no chronic wasting disease transmissibility in macaques  Chronic wasting disease did not cross the species barrier to infect cynomolgus macaque monkeys during a lengthy investigation by National Institutes of Health scientists exploring risks to humans. The study was published in the Journal of Virology.
  April 26, 2018  
• Blood Cancer precursor found in 9/11 firefighters  A study in today’s issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease, which can lead to the blood cancer multiple myeloma.
  April 26, 2018  
• FDA grants breakthrough therapy designation to Omeros' MASP-2 inhibitor OMS721  Omeros announced the FDA has granted breakthrough therapy designation to OMS721 for treatment of patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy, specifically those patients who have persistent TMA despite modification of immunosuppressive therapy.
  April 26, 2018  
• Bayer signs agreement to sell Crop Science businesses to BASF for up to 1.7 billion  In light of the proposed acquisition of Monsanto, Bayer has signed an agreement to sell further Crop Science businesses to BASF for up to 1.7 billion euros. The businesses to be sold generated total sales of 745 million euros in 2017.
  April 26, 2018  
• Two-year feasibility study results encouraging with Medtronic Harmony(TM) transcatheter  Medtronic announced two-year outcomes for the Harmony Transcatheter Pulmonary Valve from its early feasibility study. Designed to offer a treatment alternative for patients with CHD, the Harmony TPV is being studied in CHD patients born with RVOT anomalies who undergo surgical repair early in life.
  April 26, 2018  
• Alder BioPharmaceuticals® appoints Jeremy Green to its board of directors  Alder Biopharmaceuticals announced that its Board of Directors has unanimously appointed Jeremy Green, Founder and Portfolio Manager of Redmile Group, to the Company’s Board. Mr. Green will serve as a Class III director with a term expiring at the Company’s 2020 Annual Meeting.
  April 26, 2018  
• EnWave announces commercial launch of iogo protein crunchy yogurt bites  EnWave announced that Agropur Dairy Co-operative d.b.a. Ultima Foods, a royalty-partner of the Company, has successfully developed a new, innovative way of enjoying yogurt on-the-go and will be soft launching its iö:go Protein Crunch snack products in Quebec and Alberta this Spring.
  April 26, 2018  
• Achaogen wins CARB-X funding award to advance development of novel aminoglycoside  Achaogen announced it has entered into an award agreement with CARB-X. Under the agreement, Achaogen will receive an initial award of up to $2.4 million, with the possibility of up to $9.6 million more from CARB-X at its discretion based on the achievement of certain project milestones.
  April 26, 2018  

   (next 10 articles)